Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA's Drug Shortages Strategy Focuses On Prevention, Not "Empire Building"

Executive Summary

FDA would like additional funding for a number of its programs, but it does not appear that the agency will be pushing to expand its drug shortage team.

You may also be interested in...

“Comprehensive” Drug Shortage Mitigation Bill Under Development In House

Like the Senate proposal, it could include reimbursement rate adjustments in addition to requiring early notification of shortages by manufacturers, but questions remain about ensuring there are no unintended consequences.

Medicare Reimbursement Rate Targeted As Culprit For Drug Shortages

Shortages of sterile injectables stem in part from changes to Part B reimbursement made in the Medicare Modernization Act in 2003, witnesses at a House hearing argue.

Obama's Drug Shortage Efforts Focus On Personnel, Persuasion

Executive order gives FDA no new authority, but will allow doubling of shortage staff and likely bolster issue awareness.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts